The focus of the venture, established in April 2018, is to develop microbial therapies for inflammatory bowel diseases.
Nikkei Biotech news release, July 4, 2018
Hokkaido’s Kamui Pharma Co. starts on probiotic R&D
Window to Japan
Window to Japan
The focus of the venture, established in April 2018, is to develop microbial therapies for inflammatory bowel diseases.
Nikkei Biotech news release, July 4, 2018